Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1056/nejme2202547

Type

Other

Publication Date

03/2022

Volume

386

Pages

1176 - 1179

Addresses

From the Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, and the Harvard T.H. Chan School of Public Health, Boston (D.J.H.); the Centre for the Aids Programme of Research in South Africa, Durban, and the Department of Epidemiology, Columbia Mailman School of Public Health, New York (S.A.K.); and the Wellcome Trust, London (J.J.F.).

Keywords

Humans, Vaccines, COVID-19, SARS-CoV-2, COVID-19 Vaccines